4.4 Article

Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making

期刊

JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
卷 11, 期 -, 页码 295-304

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/JMDH.S160029

关键词

electronic health records; evidence-based medicine; real world data; real world evidence; randomized controlled trial

资金

  1. Pfizer

向作者/读者索取更多资源

Evidence from medication use in the real world setting can help to extrapolate and/ or augment data obtained in randomized controlled trials and establishes a broad picture of a medication's place in everyday clinical practice. By supplementing and complementing safety and efficacy data obtained in a narrowly defined (and often optimized) patient population in the clinical trial setting, real world evidence (RWE) may provide stakeholders with valuable information about the safety and effectiveness of a medication in large, heterogeneous populations. RWE is emerging as a credible information source; however, there is scope for enhancements to real world data (RWD) sources by understanding their complexities and applying the most appropriate analytical tools in order to extract relevant information. In addition to providing information for clinicians, RWE has the potential to meet the burden of evidence for regulatory considerations and may be used in approval of new indications for medications. Further understanding of RWD collection and analysis is needed if RWE is to achieve its full potential.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据